ZXDC Inhibitors
ZXDC inhibitors encompass a range of chemical compounds that reduce the functional activity of ZXDC, each acting through distinct biochemical mechanisms. Palmitoylation inhibitors, such as 2-Bromopalmitate, compromise the protein's proper localization and membrane association, an essential aspect of ZXDC's function, thereby preventing its normal activity. Similarly, methylation inhibitors like 5′-Deoxy-5′-methylthioadenosine disrupt crucial regulatory methylation pathways, impinging on ZXDC's interaction capabilities, thus leading to reduced functionality. Proteasome inhibitors, exemplified by MG-132, can cause the accumulation of misfolded or regulatory proteins, thereby obstructing ZXDC's activity. Furthermore, protein synthesis inhibitors such as Cycloheximide deplete the cellular pool of proteins necessary for ZXDC's operation, resulting in the functional attenuation of ZXDC.
The inhibition of key signaling pathways also plays a significant role in the downregulation of ZXDC's activity. Compounds like FK506 and LY 294002 disrupt specific phosphatase and kinase activities, respectively, with FK506 targeting calcineurin-dependent dephosphorylation processes, and LY 294002 inhibiting PI3K pathways critical for the activation or stability of ZXDC. MEK inhibitors such as PD 98059 and p38 MAPK inhibitors like SB 203580 alter the phosphorylation status of proteins in pathways that ZXDC may be reliant on, thus indirectly diminishing its activity. The G protein signaling inhibitor NF449 and tyrosine kinase inhibitor Genistein might also lead to reduced ZXDC functionality by disrupting protein interactions and signaling cascades. Lastly, Alsterpaullone, as a cyclin-dependent kinase inhibitor, impedes cell cycle-related signaling, further contributing to the indirect inhibition of ZXDC's functional activity by interfering with essential regulatory signals.
Items 1 to 10 of 13 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
2-Bromohexadecanoic acid | 18263-25-7 | sc-251714 sc-251714A | 10 g 50 g | $52.00 $197.00 | 4 | |
Compounds like 2-Bromopalmitate inhibit the palmitoylation process, a post-translational modification. ZXDC's function is contingent on proper localization and membrane association, which palmitoylation facilitates. Inhibition of this process impedes ZXDC's functional activity. | ||||||
Dimethyl malonate | 108-59-8 | sc-239778 sc-239778A | 250 ml 1 L | $49.00 $102.00 | 1 | |
Agents such as Dimethyl malonate block methylation pathways. Methylation is crucial for the regulation of protein interactions and function. By inhibiting methylation, ZXDC's ability to properly interact and function within the cell is diminished. | ||||||
5′-Deoxy-5′-methylthioadenosine | 2457-80-9 | sc-202427 | 50 mg | $120.00 | 1 | |
As an inhibitor of methylation reactions, 5'-Methylthioadenosine can impede protein methylation. Given that ZXDC function can be regulated through methylation status, which affects protein interactions and activity, the inhibition of methylation pathways by this compound would result in the functional diminishment of ZXDC. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 functions as a proteasome inhibitor, which can prevent the degradation of ubiquitinated proteins. If ZXDC activity is regulated by its ubiquitination status, MG-132 could lead to the accumulation of non-functional ZXDC or its regulatory proteins, thereby indirectly inhibiting its activity. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide acts as a protein synthesis inhibitor. It can indirectly inhibit ZXDC by preventing the synthesis of proteins that are essential for ZXDC's function, thus leading to a reduction in ZXDC functional activity through depletion of its supporting interactome. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $76.00 $148.00 | 9 | |
FK506 binds to FKBP and inhibits the phosphatase activity of calcineurin. Since calcineurin can dephosphorylate many proteins involved in cellular signaling, FK506 may indirectly inhibit ZXDC activity if ZXDC function is regulated by phosphorylation through pathways involving calcineurin. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor (HDACi) that can alter chromatin structure and gene expression. If ZXDC is functionally modulated by the acetylation status of histones or itself, Trichostatin A could inhibit its activity by altering the expression or activity of ZXDC or its co-regulatory proteins. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a PI3K inhibitor that can modulate various downstream signaling pathways, including those involving transcription factors and other proteins that may regulate ZXDC's function. By inhibiting PI3K, LY 294002 could hinder pathways essential for the activation or stability of ZXDC, thereby diminishing its functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 acts as a MEK inhibitor, which may inhibit the ERK/MAPK pathway. Proteins that are regulated via this pathway could affect ZXDC function. Therefore, PD 98059 may indirectly inhibit ZXDC by altering the phosphorylation status of proteins within this pathway that are essential for ZXDC's activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound is a p38 MAPK inhibitor and can modulate inflammatory signal transduction. If ZXDC function is linked to pathways influenced by p38 MAPK, SB 203580 could indirectly inhibit the protein by altering the signaling environment necessary for ZXDC's functional activity. | ||||||